ReviewCancers2026
Protein Nanocarriers: Targeted Theranostics for Cancer Treatment and Imaging.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Engineering Functional Biomaterials for Targeted and Localized Cancer Drug Delivery: A Structure-Property-Performance Design Perspective.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Protein-based nanocarriers have gained considerable attention for targeted cancer theranostic applications due to their inherent biocompatibility, biodegradability, and facile functionalisation. In addition, some of their properties, such as self-assembling nature, low immunogenicity (if species matched), molecular recognition ability, and lack of persistence due to degradation into proteinogenic amino acids, make them highly suitable for oncology-related applications. Each protein-based nanocarrier exhibits unique physicochemical and biological properties. In this review, we summarise recent advances in targeted protein-based nanocarriers, including albumin, lipoproteins, ferritin, viral protein capsids, fibrin type proteins and silk proteins, emphasising receptor-specific targeting mechanisms, the integration of various imaging modalities along with their advantages and limitations, and the importance of employing advanced preclinical models for translational theranostic applications. This review also discusses the most recent and significant studies in the field, providing useful insights into future directions of protein-based nanocarriers for cancer theranostics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.